Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus. phenprocoumon

被引:81
|
作者
Fihn, SD
Gadisseur, AAP
Pasterkamp, E
van der Meer, FJM
Breukink-Engbers, WGM
Geven-Boere, LM
van Meegen, E
de Vries-Goldschmeding, H
Antheunissn-Anneveld, I
van't Hoff, R
Harderman, D
Smink, M
Rosendaal, FR
机构
[1] Vet Affairs Puget Sound Hlth Care Syst, NW Hlth Serv Res Ctr Excellence, Seattle, WA USA
[2] Univ Washington, Dept Med, Seattle, WA USA
[3] Leiden Univ, Med Ctr, Dept Clin Epidemiol & Hemostasis, NL-2300 RA Leiden, Netherlands
[4] Leiden Univ, Med Ctr, Thrombosis Ctr, NL-2300 RA Leiden, Netherlands
[5] Oostgelderland Anticoagulat Clin, Lichtenvoorde, Netherlands
[6] Leeuwarden Anticoagulat Clin, Leeuwarden, Netherlands
[7] Anticoagulat Clin Hague, The Hague, Netherlands
[8] Dutch Red Cross, Utrecht Div, Thrombosis Ctr, Utrecht, Netherlands
[9] Schiedam Anticoagulat Clin, Schiedam, Netherlands
[10] Anticoagulat Clin Midden Brabant, Brabant, Netherlands
[11] Anticoagulat Serv Alkmaar, Alkmaar, Netherlands
关键词
anticoagulation; international normalised ratio; phenprocoumon; acenocoumarol;
D O I
10.1160/TH02-10-0179
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Variability in the control of oral anticoagulant therapy has been associated with a heightened risk of complications. We compared, control of anticoagulation between two commonly used coumarins, phenprocournon and acenocoumarol, and among anticoagulation clinics. All qualifying patients were managed at six regional anticoagulation clinics in the Netherlands. This retrospective cohort study compiled data during a three-year period from a computerised dosing and management system. Anticoagulation control was expressed as the percent of time within the therapeutic range and stability expressed as the time-weighted variance in the international normalised ratio (INR). Data were available for 22,178 patients of whom 72% were treated with acenocoumarol. INRs of patients who received phenprocoumon were within the therapeutic range 50% of the time compared with 43% for acenocoumarol (OR 1.32,95% Cl 1.24-1.41). Moreover, patients on phenprocoumon required 15% fewer monitoring visits and had more stable INR values. These observations were consistent for all six clinics. There were also sizable differences between the clinics with respect to control and stability of anticoagulation that were stable from year-to-year and were unrelated to the drug used. With its longer half-life of three to five days, phenprocoumon produces more stable anticoagulation than acenocoumarol and should generally be the drug of choice when these are the available choices. The differences observed among clinics suggest that certain clinics employ policies and practices resulting in better control of anti coagulation.
引用
收藏
页码:260 / 266
页数:7
相关论文
共 50 条